Navigation Links
New ability to regrow blood vessels holds promise for treatment of heart disease
Date:2/16/2012

University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.

The treatment method developed by Cockrell School of Engineering Assistant Professor Aaron Baker could allow doctors to bypass surgery and instead repair damaged blood vessels simply by injecting a lipid-incased substance into a patient. Once inside the body, the substance stimulates cell growth and spurs the growth of new blood vessels from pre-existing ones.

The method has been tested successfully on rats, and findings of the study were published recently in the Proceedings of the National Academy of Sciences.

"Others have tried using growth factors to stimulate vessel growth in clinical trials and have not been successful," said Baker, a faculty member in the school's Department of Biomedical Engineering. "We think that a major reason for this is that previous methods assumed the diseased tissues retained the ability to respond to a growth stimulus. Our method basically delivers extra components that can restore growth factor responsiveness to the tissue of patients with long-standing clinical disease."

The ability to regrow blood vessels could prove crucial to treating chronic myocardial ischemia disease, which affects up to 27 million patients in the U.S. and leads to a reduction of blood flow in the heart and lower limbs ultimately, causing organ dysfunction and failure.

Central ischemia, which effects the heart, occurs when the coronary vessels that feed blood to the heart become blocked or narrow due to a buildup of fatty deposits, or plaques. Such plaques are typically the result of a prolonged unhealthy diet or smoking, and factors like age, high blood pressure and diabetes increase the risks of the disease, Baker said.

Doctors have typically treated ischemia by physically opening the closed artery with a stent or surgically rerouting blood flow to the poorly perfused tissue. Both methods have limitations, however, and are not effective long-term.

The new method introduced by Baker and his research team builds off of a promising revascularization approach that, up until now, has shown limited efficacy in clinical trials for treating human disease.

The method combines a growth factor a substance capable of stimulating cellular growth, proliferation and cellular differentiation, as well as healing wounds known as fibroblast growth factor 2 (FGF-2) with a lipid-embedded receptor to enhance its activity.

A challenge for scientists and engineers, however, has been getting FGF-2 to bind with cell receptors the very molecules often found on the surface of the cell that receive chemical signals and direct activity in the cell from outside sources.

To overcome this, Baker's method embeds the growth factors in synthetic lipid-based nanoparticles containing a coreceptor known as syndecan-4. The nanoparticles containing co-receptors that, when delivered with the growth factor, enable improved cell binding so that the growth factor can direct the targeted cell to divide, proliferate and form new cells for tissue regrowth.

The incased substance was injected into rats with hindlimb ischemia and stimulated a complete recovery from the ischemia in just seven days.

"We hope this research will increase our understanding of how tissues become resistant to revascularization therapies and may lead to more effective treatments for this widespread and debilitating disease," said Baker, who was recognized last year with the National Institutes of Health Director's New Innovator Award.

Designed to support unusually creative new investigators with highly innovative research ideas at an early stage of their career, the award provides Baker with $1.5 million over five years to study and develop ways to regrow small blood vessels. With it, Baker is studying why previous attempts to restore blood flow to the heart have not been effective. His research aims to design new molecular tools and drug delivery methods to enable blood vessel growth in patients with diseases such as diabetes.


'/>"/>
Contact: Melissa Mixon
melissa.mixon@austin.utexas.edu
512-471-2129
University of Texas at Austin
Source:Eurekalert

Related biology news :

1. Study looks at possible link to hyper-excitability factors in epilepsy, autism and more
2. Sustainability, college athletics dont always connect
3. Diet, nutrient levels linked to cognitive ability, brain shrinkage
4. Slow road to stability for emulsions
5. Study of Yellowstone wolves improves ability to predict their responses to environmental changes
6. New materials capability to increase weapons explosive force demonstrated at Navy test range
7. NJIT professor plans 2012 sustainability workshop in Canada
8. Is sustainability science really a science?
9. After 25 years, sustainability is a growing science thats here to stay
10. Study details links between climate, groundwater availability - will help states prepare for drought
11. Bats show ability to change their ear shapes, making their hearing more flexible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
(Date:10/9/2017)... ... October 09, 2017 , ... The ... medical marijuana products targeting the needs of consumers who are incorporating medical marijuana ... place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
Breaking Biology Technology: